AFP and hepatocellular carcinoma: This finding aligns with a study investigating the efficacy of immunotherapy in unresectable HCC, which identified a ≥20% reduction in AFP within 8 weeks as an independent predictor of improved PFS (HR = 0.41, P < 0.05) (36).